Acute Myeloid Leukemia (AML) Treatment Options Explained
How induction, targeted therapy, venetoclax, APL, and transplant are typically sequenced — and why genetics and fitness change the plan
AML treatment starts with risk, fitness, and genetics — not one protocol. Fit adults often receive intensive induction, then chemo consolidation or transplant depending on genetic risk and MRD. Older or unfit patients more often receive venetoclax with a hypomethylating agent. APL follows a separate ATRA-and-arsenic path. International families considering China typically do so when donor shortage or next-step uncertainty after induction makes remote review useful.
This article covers:
- How AML differs from ALL, and why APL must be treated as its own disease
- Intensive induction versus venetoclax-based therapy for older or unfit patients
- How FLT3, IDH, NPM1, and other genetics change drugs and transplant timing
- When allogeneic or haploidentical transplant is typically discussed
- What international families often review with Chinese haematology teams
Quick Answer
Newly diagnosed AML in a fit adult is usually treated with intensive induction chemotherapy, then a second decision: more chemotherapy if genetic risk is favourable and MRD is deep, or allogeneic transplant if risk is intermediate or adverse. Patients who cannot tolerate intensive induction more often receive venetoclax plus azacitidine or decitabine. APL is treated with all-trans retinoic acid (ATRA) and arsenic trioxide, often without conventional AML induction. Commercial CD19 CAR-T used for B-ALL does not treat AML. Individual plans depend on the treating haematology team and complete records.
What AML Is, and How It Differs from ALL
Acute myeloid leukemia is a cancer of immature myeloid cells in the bone marrow and blood. It is not the same disease as acute lymphoblastic leukemia (ALL). ALL often responds to long multi-phase lymphoid chemotherapy and, in B-ALL, to CD19 immunotherapy or CAR-T. AML is planned around myeloid induction, mutation-matched inhibitors, and a much earlier transplant discussion for many intermediate- and high-risk adults.
Childhood AML is less common than childhood ALL, but when transplant is needed it is a major indication in China's paediatric registry. This page therefore also belongs with ChinaMed Waypoint's pediatric leukemia and blood disorders resources for international families facing paediatric AML, donor shortage, or post-induction uncertainty.
APL is AML — and it is not treated like other AML
Acute promyelocytic leukemia (APL) is a distinct AML subtype, typically with a PML::RARA fusion. First-line treatment is usually all-trans retinoic acid (ATRA) plus arsenic trioxide, sometimes with limited chemotherapy. Early bleeding and clotting risk need urgent specialist care. Do not assume a standard “7+3” AML induction applies to APL.
The Two Main Front-Line Paths
After APL is excluded, teams usually choose between intensive induction and a lower-intensity venetoclax-based programme. Fitness, age, organ function, and patient goals drive that fork — not the word “AML” alone.
Intensive induction (often “7+3”)
- Typically cytarabine for about seven days plus an anthracycline for about three days, with protocol variations
- A FLT3 inhibitor such as midostaurin may be added when FLT3 mutation is confirmed, if the local protocol includes it
- Gemtuzumab ozogamicin (CD33 antibody-drug conjugate) is used in selected CD33-positive, often favourable- or intermediate-risk, protocols
- After remission, high-dose cytarabine consolidation or allogeneic transplant is the next decision
Venetoclax + hypomethylating agent
- Venetoclax (a BCL-2 inhibitor) combined with azacitidine or decitabine is widely used for older or unfit adults
- Some IDH-mutated patients may receive an IDH1 or IDH2 inhibitor instead of, or sequenced with, other low-intensity therapy — confirm local availability
- Transplant can still be discussed later if a remission is achieved and fitness allows
- Tumour-lysis monitoring and infection support remain essential even though intensity is lower than “7+3”
For a wider map of leukaemia drugs that are not transplant, see leukemia treatments other than bone marrow transplant. Formulary and NMPA labels in China should be confirmed during case review rather than assumed from US or European practice.
What Doctors Usually Evaluate First
An AML plan is built from laboratory and fitness data, not from the diagnosis name alone. Typical first questions include:
Is this APL?
PML::RARA (or equivalent) testing and a coagulation picture that might signal APL change the entire pathway. Delay in recognising APL is dangerous because of early haemorrhage risk.
Cytogenetics and molecular genetics
Examples include core-binding-factor fusions (RUNX1::RUNX1T1 / t(8;21), CBFB::MYH11 / inv(16)), NPM1, FLT3-ITD or TKD, IDH1/IDH2, TP53, complex karyotype, and secondary AML after MDS. These results assign ELN-style favourable, intermediate, or adverse risk and decide whether a FLT3 or IDH inhibitor is in play.
Measurable residual disease (MRD)
After induction, MRD helps decide whether chemotherapy consolidation is enough or whether transplant should be brought forward. Persistent MRD in an otherwise “favourable” genotype often reopens the transplant discussion.
Fitness for intensive therapy
Performance status, heart function (anthracyclines), kidneys, infection, and caregiver support determine whether “7+3” or venetoclax-based therapy is realistic.
Donor landscape
If transplant is likely, HLA typing of the patient and family should start early. A haploidentical parent, sibling, or adult child can be evaluated when no fully matched unrelated donor is found.
Unsure whether this AML case needs transplant, venetoclax, or a different sequence?
A structured remote review with Chinese haematology specialists can map genetics, induction response, MRD, and family donor options — including haploidentical transplant when no full match is found — before any travel decision.
Request an AML case reviewWhen Transplant Enters the Discussion
Allogeneic haematopoietic cell transplant is a consolidation tool for selected AML, not automatic first-line treatment. It is more often considered when:
- ELN-style intermediate or adverse genetic risk
- Secondary AML after myelodysplastic syndrome (MDS)
- AML in second complete remission (CR2) after relapse
- Persistent MRD after planned induction and consolidation
- Paediatric AML with high-risk features, where transplant is used more often than in standard-risk paediatric ALL
Nationwide Chinese paediatric transplant registry data (CCBMTR, 2017–2024) list AML among the four leading indications for paediatric haematopoietic cell transplant, each roughly 17–19% of cases, alongside ALL, aplastic anemia, and thalassemia major. Haploidentical family donors accounted for about 56% of paediatric transplants in that dataset.
If a fully matched donor is not found, see AML-specific options when no full HLA match is available, the haploidentical transplant hub, and the CCBMTR 2017–2024 paediatric transplant overview.
Relapsed or Refractory AML — and Why CAR-T Is Not the ALL Pathway
If AML returns or never reaches a useful remission, teams typically re-check mutations, try salvage chemotherapy or a matched inhibitor (for example gilteritinib for relapsed FLT3-positive AML), and reassess transplant if disease can be reduced. Selected CD33-positive cases may involve gemtuzumab. Clinical trials are often part of the conversation.
CD19 CAR-T that is used for relapsed B-ALL does not treat AML. China's commercially approved CAR-T catalogue, summarised in the NMPA-approved CAR-T pipeline, covers CD19, BCMA, and CLDN18.2 products — not a standard AML CAR-T. Investigational AML cell-therapy programmes exist in research settings; they should not be assumed from a B-ALL or lymphoma CAR-T label. After transplant relapse, see options if leukemia comes back after transplant.
What May Be Different for International Families Considering China
China is not a substitute for a local treating haematologist. It is more often relevant when the bottleneck is donor speed, haploidentical experience, or uncertainty after induction. Practical points families ask about include:
- Large published haploidentical transplant volume, including family donors under protocols such as the Beijing Protocol — often faster than a prolonged unrelated-registry search while AML is in a short remission window
- Paediatric AML as a high-volume transplant indication in CCBMTR data
- Remote multidisciplinary case review so genetics, MRD, and donor options can be assessed before flights or donor mobilisation
Coordination — not clinical care — is what ChinaMed Waypoint provides, via online MDT consultation and cancer treatment coordination in China.
Supportive Care During AML Treatment
AML induction is typically an inpatient period of profound neutropenia. Infection prevention, transfusion support, and management of mucositis or bleeding are part of standard haematology care — not optional extras.
At Chinese haematology centres, supportive care alongside chemotherapy or transplant may also include integrative approaches such as acupuncture and Traditional Chinese Medicine for fatigue, sleep, and appetite. These are complementary to — never a replacement for — induction, venetoclax-based therapy, APL treatment, or transplant.
See the supportive care and Traditional Chinese Medicine resources for context on how integrative support is typically positioned during intensive haematology treatment in China.
Questions Families Should Ask the Treating Team
- Has APL been excluded, and are cytogenetics plus a myeloid NGS panel (FLT3, NPM1, IDH, TP53) already available?
- Is this intensive induction or a venetoclax-based programme — and why?
- What is the current ELN-style risk, and how would a positive MRD result change consolidation?
- Is transplant being discussed in first remission, later, or not at all?
- If no matched unrelated donor is found, has a haploidentical family donor been typed?
- What additional records would a second haematology team need for a remote review?
What International Families Can Do Next
Assemble records
Diagnosis reports, cytogenetics/FISH, NGS (FLT3, NPM1, IDH, TP53 and others), induction dates and counts, MRD results, echo/organ function, and HLA typing if transplant has been discussed.
Request remote MDT review
Chinese haematology specialists can comment on risk group, whether transplant is in play, and what extra tests are needed — without requiring a flight first.
Decide on travel only after medical fit is clear
Donor work-up and admission planning should follow eligibility confirmation, not the other way around.
Related Guides
No Full Match Donor for AML: What Are the Options?
Haploidentical family donors, mismatched unrelated donors, and cord blood when AML transplant is advised but no 10/10 match is found.
ALL Treatment Options for Adults and Children
How lymphoblastic leukemia pathways differ from AML — multi-phase chemo, TKIs, CD19 CAR-T, and paediatric versus adult plans.
Leukemia Treatments Other Than Bone Marrow Transplant
Targeted therapy, venetoclax, and immunotherapy across AML, ALL, CML, and CLL when transplant is not the first step.
Frequently Asked Questions
What is the usual first treatment for newly diagnosed AML?
Fit adults typically receive intensive induction chemotherapy, often a cytarabine-plus-anthracycline combination informally called “7+3,” sometimes with a targeted drug if a mutation such as FLT3 is present. Older or less fit patients more often start with venetoclax plus a hypomethylating agent (azacitidine or decitabine). Acute promyelocytic leukemia (APL) is treated on a separate ATRA and arsenic trioxide pathway and should not be managed as ordinary AML.
Does every AML patient need a bone marrow transplant?
No. Favourable-risk AML — for example some core-binding-factor or NPM1-mutated cases without high-risk co-mutations — is often consolidated with chemotherapy alone if a deep remission is achieved. Intermediate- and adverse-risk AML, secondary AML after MDS, persistent MRD, or AML in second remission more often lead to allogeneic transplant discussion in first or subsequent remission. The decision is individual and depends on genetics, response, fitness, and donor options.
How do FLT3, IDH, and NPM1 results change AML treatment?
FLT3 mutations are found in a substantial minority of AML (commonly cited around one-quarter to one-third of cases). When present, a FLT3 inhibitor may be added in induction (for example midostaurin in many protocols) or used at relapse (for example gilteritinib). IDH1 or IDH2 mutations may open IDH-inhibitor options. NPM1 without high-risk co-mutations often supports a more favourable, chemotherapy-consolidation path if MRD becomes negative. Molecular testing at diagnosis is therefore part of treatment planning, not an optional extra.
Is CAR-T an option for AML the way it is for B-cell ALL?
Not as a routine commercial pathway. China’s NMPA-approved CAR-T products currently target CD19 (lymphoma and adult B-ALL), BCMA (myeloma), and CLDN18.2 (selected gastric/GEJ cancer) — not AML. AML CAR-T remains investigational. For relapsed AML, teams more often discuss salvage chemotherapy, targeted inhibitors matched to mutations, gemtuzumab in selected CD33-positive cases, and allogeneic or haploidentical transplant.
When should an international family request an AML second opinion in China?
A structured review is often useful when risk group or transplant need is unclear after induction, when no fully matched donor is found, when AML arises from MDS, at first relapse, or when fitness makes intensive chemotherapy versus venetoclax-based therapy a close call. Families can usually start with a remote multidisciplinary review of existing records before any travel decision.
Medical disclaimer
ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. AML treatment selection, inhibitor choice, and transplant timing must be decided by qualified haematologists or transplant physicians based on the patient's complete records. Drug labels, hospital programmes, and donor options change; always verify current options with the treating team.
Request a Structured AML Case Review
If your family is facing newly diagnosed high-risk AML, unclear transplant need after induction, donor shortage, secondary AML, or relapse, a remote multidisciplinary review can clarify whether additional options in China should be considered — without requiring travel first.
For adult and paediatric AML — start with records, not a booking.